Vasogen Inc.
Mississauga, ON
Company Overview
Vasogen is a leader in the research and commercial development of immune modulation therapies for the treatment of cardiovascular, neurological, and other chronic inflammatory diseases. Vasogen's lead product, Celacade (immune modulation therapy), utilizes proprietary medical device technology, designed to target chronic inflammation by activating the immune system's physiological anti-inflammatory response to cells undergoing apoptosis (programmed cell death). Celacade is currently in pivotal phase III clinical trials for the treatment of chronic heart failure and peripheral arterial disease. Vasogen is also developing a new class of drugs for the treatment of additional indications, including neuro- inflammatory diseases.
Company Information
Physical Address
10-2155 Dunwin Dr.
Mississauga, ON L5L 4M1
CA
Mailing Address
10-2155 Dunwin Dr.
Mississauga, ON L5L 4M1
CA
Additional Details
Legal Name: Vasogen Inc.
Number of Employees: 80
CA
Vasogen is developing Celacade (immune modulation therapy) to target destructive chronic inflammation by activating the immune systems physiological anti-inflammatory response to apoptotic cells. Celacade utilizes a medical device technology to apply oxidative stress to a sample of a patients blood. Oxidative stress is known to induce senescence of white blood cells. The treated sample is then administered intramuscularly to the patient.
Senescent cells undergo apoptosis (programmed cell death) and are rapidly taken up by immune system cells. This cellular interaction initiates a change in the production of cytokines potent chemical messengers that regulate immune responses, including inflammation. The alteration in the balance between pro-inflammatory and anti-inflammatory cytokines has therapeutic potential in the treatment of a number of chronic inflammatory diseases.
Vasogen is also developing a new class of drugs to treat diseases characterized by chronic inflammation. These synthetic lipid-based drugs are designed to enable interaction with immune system cells. VP025, the first drug candidate in this class, is in preclinical development for the treatment of neurological conditions characterized by chronic inflammation, which may include such disorders as Alzheimers, Parkinsons and Lou Gehrigs disease (ALS).
Contacts
Glenn Neumann
Title: Director of Investor Relations
Phone: Show phone
Fax: Show fax
Email: Show email
Chris Waddick
Title: Executive Vice President & CFO
Phone: Show phone
Fax: Show fax
Email: Show email
Products
-
Celacade (immune Modulation Therapy) For Chronic Heart Failure
Chronic HF, most frequently resulting from coronary artery disease or hypertension, is a debilitating condition in which the hearts ability to function as a pump is impaired. Patients with HF experience a continuing decline in their health, resulting in an increased frequency of hospitalization and premature death. Vasogen is enrolling patients in its pivotal phase III ACCLAIM trial in chronic heart failure, in support of the regulatory approvals process. This 2, 000-patient trial is designed to demonstrate the ability of Celacade to reduce the risk of death and hospitalization in patients with advanced chronic HF. The initiation of the ACCLAIM trial was based on Vasogens successful phase II trial conducted in 73 patients with advanced chronic HF who were receiving the current standard of care. The results of this study demonstrated a significant reduction in the risk of death and hospitalization and significant improvements in both key electrocardiogram measures and a clinical composite score. Celacade was also shown to be well tolerated, with no reports of treatment-related serious adverse events or withdrawals from the trial. The Global Principal Investigator and Chairman of the Steering Committee for the ACCLAIM trial is Dr. James B. Young, Chairman, Division of Medicine, The Cleveland Clinic Foundation and Medical Director of the Kaufman Center for Heart Failure in Cleveland, Ohio. Dr. Young has played a leading role in numerous multi- center clinical trials focusing on heart failure and transplantation, and is the author of many articles appearing in journals such as The New England Journal of Medicine, Chest, and The American Journal of Cardiology.
- Celacade (immune Modulation Therapy) For Peripheral Arterial Disease (pad)
Additional Information
541710